Debu Tripathy reports on recent studies involving hormone therapy in estrogen receptor-positive breast cancer.
Debu Tripathy, editor-in-chief of CURE magazine, reports on recent studies involving hormone therapy in estrogen receptor-positive breast cancer. Two trials called SOFT and TEXT were combined and long-term follow-up results were announced at the San Antonio Breast Cancer Symposium. In the combined results, certain groups of patients, but not all, did seem to receive a benefit with tamoxifen in addition to shutting down the ovaries.
"This is an important conversation for patients to have when they are completing their therapy if their tumor is hormone-sensitive, and they're going to be getting hormone therapy and they're pre-menopausal (they're still having their periods)," he says. "For some patients, this may help."
FDA, Cancer Vaccine Updates and a Misguiding of Breast Cancer Treatment
February 5th 2024One cancer vaccine may still be years away from being available, a breast cancer test may be misguiding treatments for Black women and the review of two oncology regimens are being expedited by the FDA.
Listen
FDA to Review Inavolisib Combo for HR-Positive, HER2-Negative Breast Cancer
May 22nd 2024The Food and Drug Administration granted a breakthrough therapy designation to inavolisib plus Ibrance and fulvestrant for HR-positive, HER2-negative locally advanced or metastatic breast cancer.
Read More